What is Cerus Corporation (CERS) stock price today?

Cerus Corporation (CERS) currently trades at $2.03 per share. The stock has a market capitalization of $396.73M and a P/E ratio of —x.

Is CERS stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Cerus Corporation has a Smart Value Score of 32/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 4/9 and Altman Z-Score is -5.88.

What is Cerus Corporation's revenue and earnings?

Cerus Corporation has trailing twelve-month (TTM) revenue of $206.13M with profit margins of -7.58%. Earnings per share (EPS) is $-0.08.

Is Cerus Corporation financially healthy?

Cerus Corporation's Piotroski F-Score is 4/9 (moderate financial health). The Altman Z-Score of -5.88 places it in the distress.

CERS

Cerus Corporation

NASDAQ: CERS · HEALTHCARE · MEDICAL DEVICES

$2.03

+5.73% today

Updated 2026-04-30

Market cap

$396.73M

P/E ratio

—

P/S ratio

1.93x

EPS (TTM)

$-0.08

Dividend yield

—

52W range

$1 – $3

Volume

1.7M

Market cap

$396.73M

P/E ratio

—

P/S ratio

1.93x

EPS (TTM)

$-0.08

Dividend yield

—

52W range

$1 – $3

Volume

1.7M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

5.3

Growth

C+

4.5

Quality

2.0

Profitability

5.0

Valuation

C+

4/9

Piotroski F-Score

Moderate

-5.9

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$5.00

+146.31%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy2 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Free cash flow $4.89M — positive

+ Revenue growth 13.70% QoQ

Risks

- Altman Z -5.88 — distress zone

- Thin margins at -7.58%

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$162.05M	$156.37M	$180.27M	$206.13M	$206.13M
Net income	$-42.83M	$-37.49M	$-20.92M	$-15.63M	$-2.18M
EPS	—	—	—	—	$-0.08
Free cash flow	$-27.61M	$-47.77M	$8.52M	$8.52M	$4.89M
Profit margin	-26.43%	-23.98%	-11.60%	-7.58%	-7.58%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-04-01	JENSEN, CHRYSTAL	Buy	200,000	—
2026-04-01	GREEN, KEVIN DENNIS	Buy	200,000	—
2026-03-12	JAYARAMAN, VIVEK K	Sale	165,200	$1.66

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
CERS	$396.73M	32	5.3	2.0	5.0	4.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Cerus Corporation trades at $2.03. Our Smart Value Score of 32/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -5.88, it sits in the distress. TTM revenue stands at $206.13M. with profit margins at -7.58%.

Frequently asked questions

What is Cerus Corporation's stock price?

Cerus Corporation (CERS) trades at $2.03.

Is Cerus Corporation overvalued?

Smart Value Score 32/100 (Grade F, Strong Sell).

What is the price target of Cerus Corporation (CERS)?

The analyst target price is $5.00, representing +146.3% upside from the current price of $2.03.

What is Cerus Corporation's revenue?

TTM revenue is $206.13M.

Piotroski F-Score?

4/9 — moderate financial health.

Altman Z-Score?

-5.88 — distress.

Company info

SectorHEALTHCARE

IndustryMEDICAL DEVICES

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.cerus.com

Quick metrics

P/S ratio1.93x

ROE-25.70%

Beta1.63

50D MA$2.02

200D MA$1.77

Shares out0.20B

Float0.16B

Short ratio—

Avg volume1.7M

Performance

1 week+1.55%

1 month+13.87%

3 months-16.53%

YTD-4.37%

1 year—

3 years—

5 years—

Compare

CERS vs LLY →CERS vs JNJ →CERS vs ABBV →Stock screener →